Reported Sunday, Alnylam Presents Results From The KARDIA-2 Phase 2 Study Of Zilebesiran Added To Standard Of Care Antihypertensives In Patients With Inadequately Controlled Hypertension
Reported Sunday, Alnylam Presents Results From The KARDIA-2 Phase 2 Study Of Zilebesiran Added To Standard Of Care Antihypertensives In Patients With Inadequately Controlled Hypertension
据周日报道，Alnylam公布了针对Zilebesiran的 KARDIA-2 2期研究结果，该研究已添加到治疗标准中的高血压控制不当患者的抗高血压药中
- Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent Study Cohorts at Month 3
- A Single Dose of Zilebesiran Resulted in Clinically Significant Additive Reductions in Office Systolic Blood Pressure at Month 3 and in Time-Adjusted Office Systolic Blood Pressure at Month 6 Across Three Independent Study Cohorts
- Zilebesiran Demonstrated an Encouraging Safety and Tolerability Profile When Added to Standard of Care Antihypertensives
- 该研究达到了主要终点，表明三个独立研究队列的动态收缩压在第3个月有临床显著降低，最高可达12.1 mmHg
- 在三个独立研究群组中，单剂量的Zilebesiran使办公室收缩压在第3个月显著降低，在第6个月使经时间调整的办公室收缩压明显降低
- 将Zilebesiran添加到护理标准抗高血压药中后表现出令人鼓舞的安全性和耐受性